PL2968605T3 - Metody i kompozycje dla wektorów aav podwójnie wiążących glikan - Google Patents
Metody i kompozycje dla wektorów aav podwójnie wiążących glikanInfo
- Publication number
- PL2968605T3 PL2968605T3 PL14763050.3T PL14763050T PL2968605T3 PL 2968605 T3 PL2968605 T3 PL 2968605T3 PL 14763050 T PL14763050 T PL 14763050T PL 2968605 T3 PL2968605 T3 PL 2968605T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- aav vectors
- glycan binding
- dual glycan
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361802111P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/028545 WO2014144229A1 (en) | 2013-03-15 | 2014-03-14 | Methods and compositions for dual glycan binding aav vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2968605T3 true PL2968605T3 (pl) | 2022-11-07 |
Family
ID=51537652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14763050.3T PL2968605T3 (pl) | 2013-03-15 | 2014-03-14 | Metody i kompozycje dla wektorów aav podwójnie wiążących glikan |
Country Status (12)
Country | Link |
---|---|
US (3) | US10077291B2 (pl) |
EP (2) | EP2968605B1 (pl) |
JP (4) | JP6396988B2 (pl) |
CN (2) | CN110885854A (pl) |
AU (4) | AU2014227766B2 (pl) |
CA (1) | CA2904396A1 (pl) |
DK (1) | DK2968605T3 (pl) |
ES (1) | ES2926774T3 (pl) |
IL (5) | IL298049B2 (pl) |
PL (1) | PL2968605T3 (pl) |
PT (1) | PT2968605T (pl) |
WO (1) | WO2014144229A1 (pl) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
CA2833905C (en) | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
CA3049237A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
US9226976B2 (en) | 2011-04-21 | 2016-01-05 | University Of Massachusetts | RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
US9677088B2 (en) * | 2012-05-09 | 2017-06-13 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
IL298049B2 (en) * | 2013-03-15 | 2023-10-01 | Univ North Carolina Chapel Hill | Methods and compounds for ligation of paired AAV glycan vectors |
EP3633041A3 (en) | 2013-09-26 | 2020-07-29 | University of Florida Research Foundation, Inc. | Synthetic combinatorial aav capsid library for targeted gene therapy |
US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
EP3750907A3 (en) | 2014-03-18 | 2021-04-28 | University of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
US10689653B2 (en) | 2014-06-03 | 2020-06-23 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
EP3795580A1 (en) | 2014-10-03 | 2021-03-24 | University of Massachusetts | High efficiency library-identified aav vectors |
JP7023108B2 (ja) | 2014-10-21 | 2022-02-21 | ユニバーシティ オブ マサチューセッツ | 組み換えaavバリアントおよびその使用 |
SI3233129T1 (sl) | 2014-12-17 | 2020-07-31 | Fundacion Para La Investigacion Medica Aplicada | Konstrukti nukleinske kisline in vektorji genske terapije za uporabo pri zdravljenju Wilsonove bolezni in drugih stanj |
CN107208105A (zh) | 2014-12-17 | 2017-09-26 | 基础应用医学研究基金会 | 用于治疗威尔森病的核酸构建体和基因治疗载体 |
WO2016131009A1 (en) | 2015-02-13 | 2016-08-18 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
PT3356390T (pt) | 2015-09-28 | 2021-04-21 | Univ Florida | Métodos e composições para vetores virais que se evadem a anticorpos |
CA3002980A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
CA3002982A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
MX2018005084A (es) | 2015-11-05 | 2019-05-16 | Bamboo Therapeutics Inc | Genes de ataxia de friedreich modificados y vectores para terapia genica. |
CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
EP4094780A3 (en) | 2016-02-12 | 2023-02-08 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
EP3419639A4 (en) | 2016-02-22 | 2019-08-07 | The University of North Carolina at Chapel Hill | AAV IDUA VECTOR FOR TREATING BLINDNESS IN CONNECTION WITH MPS I |
EP3440210A4 (en) | 2016-04-05 | 2019-11-27 | University of Massachusetts | COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF EXPRESSION OF GRAINHEAD PROTEIN |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
WO2017181105A1 (en) | 2016-04-15 | 2017-10-19 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
US11564997B2 (en) | 2016-06-29 | 2023-01-31 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
US11174469B2 (en) | 2016-06-29 | 2021-11-16 | Crispr Therapeutics Ag | Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders |
EP3478829A1 (en) | 2016-06-29 | 2019-05-08 | Crispr Therapeutics AG | Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders |
US20190240353A1 (en) * | 2016-07-05 | 2019-08-08 | University Of Massachusetts | Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma |
US11459587B2 (en) | 2016-07-06 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
JP7305534B2 (ja) | 2016-07-06 | 2023-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛関連障害を処置するための物質及び方法 |
EP3491015A4 (en) | 2016-07-26 | 2020-02-26 | The University of North Carolina at Chapel Hill | IMMUNE TOLERANCE INDUCED BY VECTORS IN THE EYE |
BR112019002904A2 (pt) * | 2016-08-16 | 2019-06-25 | Univ North Carolina Chapel Hill | métodos e composições para transferência gênica direcionada |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
JP7237843B2 (ja) | 2017-02-21 | 2023-03-13 | ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. | 修飾されたaavキャプシドタンパク質およびその使用 |
WO2018154459A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders |
WO2018154387A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
WO2018154418A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
WO2018154439A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
EP3589311A1 (en) | 2017-03-02 | 2020-01-08 | Genethon | Method for removing anti-aav antibodies from a blood-derived composition |
JP7327803B2 (ja) | 2017-05-09 | 2023-08-16 | ユニバーシティ オブ マサチューセッツ | 筋萎縮性側索硬化症(als)を処置する方法 |
EP3625344A1 (en) | 2017-05-15 | 2020-03-25 | University of Florida Research Foundation, Inc. | Core master regulators of glioblastoma stem cells |
EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019060686A1 (en) | 2017-09-22 | 2019-03-28 | University Of Massachusetts | NEW DUAL EXPRESSION VECTORS OF SOD1 AND USES THEREOF |
US10662425B2 (en) | 2017-11-21 | 2020-05-26 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
CN111836892A (zh) | 2017-12-21 | 2020-10-27 | 克里斯珀医疗股份公司 | 用于治疗2a型乌谢尔综合征的材料和方法 |
JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
SG11202009450SA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Virus vectors for targeting ophthalmic tissues |
WO2019219649A1 (en) | 2018-05-14 | 2019-11-21 | Vivet Therapeutics | Gene therapy vectors comprising s/mar sequences |
TW202015742A (zh) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒(aav)之組成物和方法 |
US20210198691A1 (en) | 2018-05-15 | 2021-07-01 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
CN112770812A (zh) | 2018-07-24 | 2021-05-07 | 沃雅戈治疗公司 | 产生基因治疗制剂的系统和方法 |
CN113383010A (zh) | 2018-09-28 | 2021-09-10 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
EP3863682B1 (en) | 2018-10-12 | 2023-05-17 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
SG11202104634UA (en) | 2018-11-07 | 2021-06-29 | Vivet Therapeutics | Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2) |
TW202039858A (zh) | 2019-01-18 | 2020-11-01 | 美商航海家醫療公司 | 用於生產aav顆粒之方法及系統 |
CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
TW202102526A (zh) * | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
US20220194992A1 (en) * | 2019-04-26 | 2022-06-23 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav2.5 vector |
US20240124889A1 (en) | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
WO2020264254A1 (en) | 2019-06-28 | 2020-12-30 | Crispr Therapeutics Ag | Materials and methods for controlling gene editing |
CN114729331A (zh) | 2019-07-11 | 2022-07-08 | 法国国家科学研究中心 | 化学修饰的腺相关病毒 |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
EP4045525A1 (en) | 2019-10-17 | 2022-08-24 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
KR20230020394A (ko) | 2020-04-15 | 2023-02-10 | 보이저 테라퓨틱스, 인크. | Tau 결합 화합물 |
GB202005732D0 (en) | 2020-04-20 | 2020-06-03 | Synpromics Ltd | Regulatory nucleic acid sequences |
US20210348197A1 (en) * | 2020-05-05 | 2021-11-11 | The University Of North Carolina At Chapel Hill | Modified adeno-associated virus 5 capsids and uses thereof |
AU2021273447A1 (en) | 2020-05-13 | 2022-12-08 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
US20230227802A1 (en) | 2020-07-27 | 2023-07-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
WO2022093769A1 (en) * | 2020-10-28 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav2.5 vector |
CN116490514A (zh) | 2020-10-28 | 2023-07-25 | 北卡罗来纳-查佩尔山大学 | 用于双重聚糖结合aav2.5载体的方法和组合物 |
IL302608A (en) | 2020-11-03 | 2023-07-01 | Pfizer | Methods for producing AAV vectors using ion exchange chromatography |
WO2022130172A1 (en) | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins |
AU2021404944A1 (en) | 2020-12-23 | 2023-07-06 | Pfizer Inc. | Methods for purification of aav vectors by affinity chromatography |
WO2022136616A1 (en) | 2020-12-23 | 2022-06-30 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
TW202242124A (zh) | 2021-01-14 | 2022-11-01 | 美商史崔德生物公司 | 靶向t細胞之aav載體 |
WO2022208342A1 (en) | 2021-04-01 | 2022-10-06 | Pfizer Inc. | Pharmaceutical compositions containing adeno-associated viral vector |
CN113121653B (zh) * | 2021-04-19 | 2021-11-19 | 上海信致医药科技有限公司 | 肌肉和视网膜特异性的新型腺相关病毒衣壳蛋白 |
AU2022281825A1 (en) | 2021-05-28 | 2024-01-18 | Shanghai Regenelead Therapies Co., Ltd. | Recombinant adeno-associated virus having variant capsid, and application thereof |
CA3224755A1 (en) | 2021-06-22 | 2022-12-29 | Pfizer Inc. | Production of adeno-associated virus vector in insect cells |
WO2023114816A1 (en) | 2021-12-14 | 2023-06-22 | Neurogene, Inc. | Recombinant optimized galc constructs and methods for treating galc-associated disorders |
WO2023111580A1 (en) | 2021-12-16 | 2023-06-22 | University Of Dundee | Targeted degradation of alpha-synuclein |
GB202201242D0 (en) | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
TW202342759A (zh) | 2022-02-04 | 2023-11-01 | 美商史崔德生物公司 | 重組腺相關病毒載體及其使用方法 |
GB202201713D0 (en) | 2022-02-10 | 2022-03-30 | Univ Dundee | An affinity directed phosphatase system for targeted protein dephosphorylation |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
WO2023198652A1 (en) | 2022-04-11 | 2023-10-19 | Centre National De La Recherche Scientifique | Chemically-modified adeno-associated viruses |
CN116970648A (zh) * | 2022-04-24 | 2023-10-31 | 上海朗昇生物科技有限公司 | 新型aav衣壳改造株及其用途 |
GB202206336D0 (en) | 2022-04-29 | 2022-06-15 | Univ Edinburgh | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders |
WO2023214346A1 (en) | 2022-05-06 | 2023-11-09 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
WO1988002026A1 (en) | 1986-09-08 | 1988-03-24 | Applied Biotechnology, Inc. | Empty viral capsid vaccines |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
EP0442926A1 (en) | 1988-11-10 | 1991-08-28 | Imperial Cancer Research Technology Limited | Polypeptides |
US5916563A (en) | 1988-11-14 | 1999-06-29 | United States Of America | Parvovirus protein presenting capsids |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
ES2026826A6 (es) | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados. |
US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
DE69638103D1 (de) | 1995-06-07 | 2010-02-04 | Univ North Carolina | Die transduktion von myoblasten mittels vektoren aus adenoassoziierten viren |
US6083702A (en) | 1995-12-15 | 2000-07-04 | Intronn Holdings Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
EP0883344B2 (en) | 1995-12-15 | 2010-06-09 | VIRxSYS Corporation | Therapeutic molecules generated by trans-splicing |
US20030215422A1 (en) | 1996-09-11 | 2003-11-20 | John A. Chiorini | Aav4 vector and uses thereof |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
NL1006686C2 (nl) | 1997-07-30 | 1999-02-02 | Tno | Werkwijze en inrichting voor het sorteren van tapijt of soortgelijke stukken textiel. |
CA2347129A1 (en) | 1998-09-22 | 2000-03-30 | University Of Florida | Methods for large-scale production of recombinant aav vectors |
JP4573437B2 (ja) | 1998-11-05 | 2010-11-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス血清型1核酸配列、ベクターおよび同一物を含有する宿主細胞 |
EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
NZ522841A (en) | 2000-06-01 | 2004-12-24 | Univ North Carolina | Surgically implantable matrix with a viral vector dried onto it for controlled release of recombinant parvovirus vectors |
CA2410828C (en) | 2000-06-01 | 2012-01-24 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US6623729B2 (en) | 2001-07-09 | 2003-09-23 | Korea Advanced Institute Of Science And Technology | Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer |
US7071172B2 (en) | 2002-04-30 | 2006-07-04 | The University Of North Carolina At Chapel Hill | Secretion signal vectors |
ITRM20020253A1 (it) | 2002-05-08 | 2003-11-10 | Univ Roma | Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. |
US9233131B2 (en) * | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US7906111B2 (en) * | 2003-09-30 | 2011-03-15 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor |
FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
CN101056539B (zh) | 2004-09-09 | 2012-12-12 | 综合医院公司 | 调节心脏细胞中的磷酸酶活性 |
US20080213759A1 (en) | 2005-01-05 | 2008-09-04 | Shionogi & Co., Ltd. | Novel Angiogenesis Inhibitor |
CN101213203A (zh) | 2005-04-29 | 2008-07-02 | 教堂山北卡罗莱纳州大学 | 在转录后水平调节核酸表达的方法和组合物 |
EP1981548A4 (en) | 2006-01-20 | 2010-03-24 | Univ North Carolina | ENHANCED PRODUCTION OF INFECTIOUS VECTORS OF PARVOVIRUS IN INSECT CELLS |
WO2007089632A2 (en) * | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
CA2638913A1 (en) | 2006-02-10 | 2007-09-07 | The University Of Cincinnati | Phosphatase inhibitor protein-1 as a regulator of cardiac function |
EP2125006B1 (en) | 2007-01-18 | 2013-10-16 | University of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
WO2010031865A1 (en) * | 2008-09-19 | 2010-03-25 | Charitē Universitätsmedizin Berlin | Identification and characterisation of recombinant viral gene therapy vectors |
EP2396343B1 (en) * | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
WO2012109214A1 (en) * | 2011-02-07 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Targeted transduction of aav vectors |
US9409953B2 (en) * | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
TR201908020T4 (tr) * | 2011-02-17 | 2019-06-21 | Univ Pennsylvania | Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler. |
US9677088B2 (en) * | 2012-05-09 | 2017-06-13 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
IL298049B2 (en) * | 2013-03-15 | 2023-10-01 | Univ North Carolina Chapel Hill | Methods and compounds for ligation of paired AAV glycan vectors |
-
2014
- 2014-03-14 IL IL298049A patent/IL298049B2/en unknown
- 2014-03-14 US US14/777,070 patent/US10077291B2/en active Active
- 2014-03-14 EP EP14763050.3A patent/EP2968605B1/en active Active
- 2014-03-14 ES ES14763050T patent/ES2926774T3/es active Active
- 2014-03-14 AU AU2014227766A patent/AU2014227766B2/en active Active
- 2014-03-14 EP EP20213132.2A patent/EP3838297A1/en active Pending
- 2014-03-14 IL IL293294A patent/IL293294B2/en unknown
- 2014-03-14 WO PCT/US2014/028545 patent/WO2014144229A1/en active Application Filing
- 2014-03-14 PL PL14763050.3T patent/PL2968605T3/pl unknown
- 2014-03-14 JP JP2016502819A patent/JP6396988B2/ja active Active
- 2014-03-14 DK DK14763050.3T patent/DK2968605T3/da active
- 2014-03-14 CA CA2904396A patent/CA2904396A1/en active Pending
- 2014-03-14 CN CN201911023210.1A patent/CN110885854A/zh active Pending
- 2014-03-14 PT PT147630503T patent/PT2968605T/pt unknown
- 2014-03-14 CN CN201480025514.0A patent/CN105163764B/zh active Active
-
2015
- 2015-08-20 IL IL240738A patent/IL240738B/en active IP Right Grant
-
2018
- 2018-08-23 US US16/110,773 patent/US11059862B2/en active Active
- 2018-08-28 JP JP2018159034A patent/JP6643429B2/ja active Active
- 2018-12-20 AU AU2018282408A patent/AU2018282408B2/en active Active
-
2019
- 2019-11-19 IL IL270765A patent/IL270765B/en active IP Right Grant
- 2019-12-27 JP JP2019237943A patent/JP7012376B2/ja active Active
-
2020
- 2020-12-08 IL IL279292A patent/IL279292B/en unknown
- 2020-12-11 US US17/119,308 patent/US20210115091A1/en active Pending
- 2020-12-31 AU AU2020294360A patent/AU2020294360B2/en active Active
-
2022
- 2022-01-11 JP JP2022002145A patent/JP7209402B2/ja active Active
- 2022-10-20 AU AU2022256172A patent/AU2022256172A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL298049B1 (en) | Methods and compounds for ligation of paired aav glycan vectors | |
IL286859A (en) | Adeno-associated virus factor viii vectors | |
HK1219966A1 (zh) | 結合蛋白 | |
IL240915A0 (en) | Dual-specific binding proteins directed against tnfɑ | |
HK1213271A1 (zh) | 高度糖基化的結合多肽 | |
HK1210793A1 (en) | Abd binding polypeptide | |
SG11201604663SA (en) | Cd44 binding peptides | |
HK1218920A1 (zh) | 改善的 結合蛋白 | |
ZA201507808B (en) | Binding element | |
HRP20181700T1 (hr) | Fascikl | |
ZA201707980B (en) | Binding folder | |
GB201508729D0 (en) | Binding molecules | |
GB201313149D0 (en) | Elastic binding system | |
GB201312200D0 (en) | Heparin binding peptides | |
GB201314294D0 (en) | Binding surfaces | |
GB201303977D0 (en) | Binding polypeptides |